The team at Third Harmonic Bio is on a mission — we are driven to advance the next wave of medicine for allergy and inflammation. We are grounded in our purpose: developing a medicine that can meaningfully improve the lives of the patients we serve. We cultivate transparency and accessibility, with the knowledge that we can only achieve great things if we are in this together. And we keep going. Because we have something important to offer. And if it were easy, everyone would do it. Come join us.
We are developing a novel highly selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Early clinical studies demonstrate that KIT inhibition has the potential to revolutionize the treatment of a broad range of mast-cell-mediated inflammatory diseases, and that a titratable, oral, intracellular small molecule inhibitor may provide the optimal therapeutic profile against this target.
Our singular purpose is to create a breakthrough treatment for people living with severe allergy and inflammation—debilitating conditions that can take a significant toll on patients’ overall health and well-being.
Our values provide the scaffolding for our culture and our operating principles —with each other, with our collaborators, and with the global medical and patient community at large.
Third Harmonic Bio is led by a proven executive team with a successful track record of building great companies, developing impactful medicines, and delivering value to all stakeholders: our patients, our employees, and our shareholders.
Edward R. Conner, M.D.
Gregg Keaney, Ph.D.
Adrian S. Ray
David Bonita, M.D.
Mark Iwicki (Chairman)
Martin Seidel, Ph.D.
Thomas M. Soloway
Mast cells are the primary effector cells of inflammatory diseases of the skin and respiratory, which collectively affect millions of people worldwide. In their most severe forms, these diseases are associated with significant morbidity. Despite significant investment in the field and the availability of several approved therapies, there remains a significant unmet need in the treatment of these diseases.
Targeting mast cells directly through highly selective inhibition of KIT represents a novel therapeutic approach and may be key to achieving the clinical efficacy needed for broad symptomatic relief across a range of allergic and other inflammatory disorders. The ideal therapeutic profile would combine the target selectivity and potency of a biologic with the ease of administration that an oral small molecule affords.
We’re advancing a highly selective, oral small molecule inhibitor of KIT for the treatment of multiple mast cell-driven inflammatory conditions that share similar pathophysiology, including dermal, respiratory and gastrointestinal diseases. We are currently in preclinical development with multiple product candidates in exploratory toxicology studies. We plan to nominate a development candidate in 2023.
We do this together.
We keep going.